JP2023514407A5 - - Google Patents
Info
- Publication number
- JP2023514407A5 JP2023514407A5 JP2022550184A JP2022550184A JP2023514407A5 JP 2023514407 A5 JP2023514407 A5 JP 2023514407A5 JP 2022550184 A JP2022550184 A JP 2022550184A JP 2022550184 A JP2022550184 A JP 2022550184A JP 2023514407 A5 JP2023514407 A5 JP 2023514407A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cells
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980914P | 2020-02-24 | 2020-02-24 | |
| US62/980,914 | 2020-02-24 | ||
| US202063020713P | 2020-05-06 | 2020-05-06 | |
| US63/020,713 | 2020-05-06 | ||
| US202063053409P | 2020-07-17 | 2020-07-17 | |
| US63/053,409 | 2020-07-17 | ||
| US202063092681P | 2020-10-16 | 2020-10-16 | |
| US63/092,681 | 2020-10-16 | ||
| PCT/US2021/019362 WO2021173630A1 (en) | 2020-02-24 | 2021-02-24 | Bcma car-t cells with enhanced activities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514407A JP2023514407A (ja) | 2023-04-05 |
| JP2023514407A5 true JP2023514407A5 (cg-RX-API-DMAC7.html) | 2024-03-04 |
Family
ID=75108802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550184A Pending JP2023514407A (ja) | 2020-02-24 | 2021-02-24 | 増強された活性を有するbcma car-t細胞 |
Country Status (15)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230138428A1 (en) * | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| KR20230171994A (ko) | 2021-04-16 | 2023-12-21 | 셀진 코포레이션 | 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법 |
| WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| CN117126856A (zh) * | 2022-05-20 | 2023-11-28 | 上海雅科生物科技有限公司 | 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用 |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| CN119836438A (zh) * | 2022-09-19 | 2025-04-15 | 艾洛基治疗公司 | B-细胞成熟抗原(bcma)抗独特型抗体 |
| US20260166082A1 (en) | 2022-11-02 | 2026-06-18 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| US20260108629A1 (en) * | 2024-08-14 | 2026-04-23 | Kite Pharma, Inc. | Vectors for production of therapeutic constructs |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) * | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| EP2694640B1 (en) | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI700298B (zh) * | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向b細胞成熟抗原之嵌合型抗原受體類 |
| WO2016168612A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| WO2019055946A1 (en) | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| CN118546961A (zh) * | 2016-08-26 | 2024-08-27 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| US11654158B2 (en) | 2016-11-17 | 2023-05-23 | 2Seventy Bio, Inc. | TGFBeta signal convertor |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| SG11201908929VA (en) * | 2017-03-31 | 2019-10-30 | Univ Leland Stanford Junior | Synthekine compositions and methods of use |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| AU2019227979B2 (en) * | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN112533942A (zh) * | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
-
2021
- 2021-02-24 PE PE2022001799A patent/PE20221757A1/es unknown
- 2021-02-24 AU AU2021227191A patent/AU2021227191A1/en active Pending
- 2021-02-24 CA CA3167065A patent/CA3167065A1/en active Pending
- 2021-02-24 MX MX2022010340A patent/MX2022010340A/es unknown
- 2021-02-24 IL IL295470A patent/IL295470A/en unknown
- 2021-02-24 KR KR1020227030983A patent/KR20220145846A/ko active Pending
- 2021-02-24 JP JP2022550184A patent/JP2023514407A/ja active Pending
- 2021-02-24 CN CN202180016621.7A patent/CN115175929A/zh active Pending
- 2021-02-24 BR BR112022016657A patent/BR112022016657A2/pt not_active IP Right Cessation
- 2021-02-24 WO PCT/US2021/019362 patent/WO2021173630A1/en not_active Ceased
- 2021-02-24 US US17/183,689 patent/US12036243B2/en active Active
- 2021-02-24 TW TW110106494A patent/TWI894211B/zh active
- 2021-02-24 PH PH1/2022/552033A patent/PH12022552033A1/en unknown
- 2021-02-24 EP EP21713206.7A patent/EP4110805A1/en active Pending
-
2022
- 2022-08-19 CO CONC2022/0011684A patent/CO2022011684A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7836847B2 (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| JP2023139070A5 (cg-RX-API-DMAC7.html) | ||
| CN111527109B (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2020096630A5 (cg-RX-API-DMAC7.html) | ||
| US9868961B2 (en) | Methods and compositions for localized secretion of anti-CTLA-4 antibodies | |
| CN112074278B (zh) | Bcma-car-t细胞 | |
| CA2926267C (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
| JP2022506598A5 (cg-RX-API-DMAC7.html) | ||
| JP2014532074A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512882A5 (cg-RX-API-DMAC7.html) | ||
| JP2020512019A5 (cg-RX-API-DMAC7.html) | ||
| AU2016313107A1 (en) | Conditionally active chimeric antigen receptors for modified T-cells | |
| JP2022521240A5 (cg-RX-API-DMAC7.html) | ||
| CA3177234A1 (en) | Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof | |
| JP2019536469A5 (cg-RX-API-DMAC7.html) | ||
| KR20240004680A (ko) | 키메라 수용체 및 이의 사용 방법 | |
| JP2023553049A (ja) | Cd19+、cd20+、若しくはcd22+腫瘍又はb細胞由来の自己免疫疾患を治療するためのcar t細胞 | |
| CN110938148A (zh) | 靶向cd19和cd22嵌合抗原受体 | |
| JP7619682B2 (ja) | Cd22に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| WO2017195749A1 (ja) | キメラ抗原受容体、及びその利用 | |
| KR20230143108A (ko) | Cd30 유래의 세포내 신호전달 도메인을 포함하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 | |
| EP4301402A1 (en) | Bispecific antibodies enhancing cell mediated immune responses | |
| WO2023016554A1 (zh) | 靶向cd22的抗原结合蛋白及其用途 | |
| US20220144953A1 (en) | Vista-binding antibodies and uses thereof | |
| TW202540184A (zh) | 一種靶向cd7的人源化抗體、嵌合抗原受體及其應用 |